Evidence map›Paper›PMID 37686518›Full record

ArticleCancers2023

Clinico-Pathological Features, Outcomes and Impacts of COVID-19 Pandemic on Patients with Early-Onset Colorectal Cancer: A Single-Institution Experience.

Daniel Martinez-Perez, David Viñal, Jesús Peña-Lopez, Diego Jimenez-Bou, Iciar Ruiz-Gutierrez, Sergio Martinez-Recio, María Alameda-Guijarro, Antonio Rueda-Lara, Gema Martin-Montalvo, Ismael Ghanem and 14 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Daniel Martinez-PerezDepartment of Medical Oncology, Central University Hospital of Asturias, 33011 Oviedo, Spain.
David ViñalDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Jesús Peña-LopezDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.ORCID 0000-0003-1100-8211
Diego Jimenez-BouDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Iciar Ruiz-GutierrezDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Sergio Martinez-RecioDepartment of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
María Alameda-GuijarroDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Antonio Rueda-LaraDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Gema Martin-MontalvoDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Ismael GhanemDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Ana Belén CustodioDepartment of Medical Oncology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Lucia Trilla-FuertesMolecular Oncology and Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.ORCID 0000-0002-4452-3474
Angelo Gamez-PozoMolecular Oncology and Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM, Hospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.
Antonio BarbachanoInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.ORCID 0000-0002-1248-5143
Javier Rodriguez-CobosInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.ORCID 0000-0003-1948-0326
Pilar Bustamante-MadridInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.
Asuncion Fernandez-BarralInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.ORCID 0000-0002-1278-4645
Aurora BurgosDepartment of Gastroenterology, Hospital Universitario La Paz, 28046 Madrid, Spain.
Maria Isabel Prieto-NietoInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.
Laura Guerra PastrianCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.ORCID 0000-0002-8478-8522
José Manuel González-SanchoInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.
Alberto MuñozInstituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), 28046 Madrid, Spain.ORCID 0000-0003-3890-4251
Jaime FeliuDepartment of Medical Oncology, Central University Hospital of Asturias, 33011 Oviedo, Spain.ORCID 0000-0003-4867-1420
Nuria Rodríguez-SalasDepartment of Medical Oncology, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Funding

Instituto de Salud Carlos III ICI20/00057, CIBERONC/CB16/12/00273, CIBERONC/CB16/12/00398
6 · The paper itself

Abstract

backgroundThe rising incidence of colorectal cancer (CRC) among young patients is alarming. We aim to characterize the clinico-pathological features and outcomes of patients with early-onset CRC (EOCRC), as well as the impacts of COVID-19 pandemic.

methodsWe included all patients with pathologically confirmed diagnoses of CRC at Hospital Universitario La Paz from October 2016 to December 2021. The EOCRC cut-off age was 50 years old.

resultsA total of 1475 patients diagnosed with CRC were included, eighty (5.4%) of whom had EOCRC. Significant differences were found between EOCRC and later-onset patients regarding T, N stage and metastatic presentation at diagnosis; perineural invasion; tumor budding; high-grade tumors; and signet ring cell histology, with all issues having higher prevalence in the early-onset group. More EOCRC patients had the RAS/ BRAF wild type. Chemotherapy was administered more frequently to patients with EOCRC. In the metastatic setting, the EOCRC group presented a significantly longer median OS. Regarding the COVID-19 pandemic, more patients with COVID-19 were diagnosed with metastatic disease (61%) in the year after the lockdown (14 March 2020) than in the pre-pandemic EOCRC group (29%).

conclusionsEOCRC is diagnosed at a more advanced stage and with worse survival features in localized patients. More patients with EOCRC were diagnosed with metastatic disease in the year after the COVID-19 pandemic lockdown. The long-term consequences of COVID-19 are yet to be determined.

Indexed as

COVID-19 pandemicearly-onset colorectal cancerprognosis

Identifiers

PMID37686518
PMCPMC10487095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.